Multimodality vendor GE Healthcare of Chalfont St. Giles, U.K., has signed an agreement with pharmaceutical developer Eli Lilly of Indianapolis covering research into compounds that could be developed into diagnostic and therapeutic agents for Alzheimer's disease.
The deal gives GE access to Eli Lilly's molecular libraries to search for compounds that could become targeted Alzheimer's diagnostic agents. In turn, Lilly will have access to any diagnostic agents that GE develops under the collaboration for use in the discovery, development, and validation of Alzheimer's disease therapeutic pharmaceuticals.
The companies believe they can accelerate the process of developing new Alzheimer's drugs by sharing molecular libraries, research findings, and other resources. One goal of the collaboration is to develop a diagnostic agent capable of detecting Alzheimer's disease in patients before they show signs of cognitive impairment, according to GE.
By AuntMinnie.com staff writers
April 20, 2005
Related Reading
GE Healthcare's Q1 sales grow 33%, April 18, 2005
Wood promoted at GE, April 12, 2005
GE assists museums with mummy scans, April 8, 2005
GE makes ultrasound donation to Haiti program, April 6, 2005
GE signs HealthTrust, April 4, 2005
Copyright © 2005 AuntMinnie.com
